FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study

L M Paterson, D Barker, S Cro, P Mozgunov, R Phillips, C Smith, L Nahar, S Paterson, A R Lingford-Hughes, L M Paterson, D Barker, S Cro, P Mozgunov, R Phillips, C Smith, L Nahar, S Paterson, A R Lingford-Hughes

Abstract

Background: Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems with opiate withdrawal. Preclinical and preliminary clinical evidence suggests that the GABA-B agonist, baclofen, has the desired properties to facilitate opiate detoxification and prevent relapse. This study aims to understand whether there are any safety issues in administering baclofen to opioid-dependent individuals receiving methadone.

Methods: Opiate-dependent individuals (DSM-5 severe opioid use disorder) maintained on methadone will be recruited from addiction services in northwest London (NHS and third sector providers). Participants will be medically healthy with no severe chronic obstructive pulmonary disease or type 2 respiratory failure, no current dependence on other substances (excluding nicotine), no current severe DSM-5 psychiatric disorders, and no contraindications for baclofen or 4800 IU vitamin D (placebo). Eligible participants will be randomised in a 3:1 ratio to receive baclofen or placebo in an adaptive, single-blind, ascending dose design. A Bayesian dose-escalation model will inform the baclofen dose (10, 30, 60, or 90 mg) based on the incidence of 'dose-limiting toxicity' (DLT) events and participant-specific methadone dose. A range of respiratory, cardiovascular, and sedative measures including the National Early Warning Score (NEWS2) and Glasgow Coma Scale will determine DLT. On the experimental day, participants will consume their usual daily dose of methadone followed by an acute dose of baclofen or placebo (vitamin D3) ~ 1 h later. Measures including oxygen saturation, transcutaneous CO2, respiratory rate, QTc interval, subjective effects (sedation, drug liking, craving), plasma levels (baclofen, methadone), and adverse events will be obtained using validated questionnaires and examinations periodically for 5 h after dosing.

Discussion: Study outcomes will determine what dose of baclofen is safe to prescribe to those receiving methadone, to inform a subsequent proof-of-concept trial of the efficacy baclofen to facilitate opiate detoxification. To proceed, the minimum acceptable dose is 30 mg of baclofen in patients receiving ≤ 60 mg/day methadone based on the clinical experience of baclofen's use in alcoholism and guidelines for the management of opiate dependence.

Trial registration: Clinicaltrials.gov NCT05161351. Registered on 16 December 2021.

Keywords: Adaptive; Addiction; Baclofen; Bayesian; Dependence; Dose escalation; GABA-B; Methadone; Opiate; Phase I.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

References

    1. ONS. Deaths related to drug poisoning in England and Wales: 2017 registrations. UK: Office for National Statistics; 2018. [Available from: ]
    1. Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend. 2011;115(3):190–195. doi: 10.1016/j.drugalcdep.2010.10.021.
    1. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51. doi: 10.1111/j.1360-0443.2010.03140.x.
    1. UK Home Office . HM Government 2017 Drug Strategy: UK Home Office. 2017.
    1. ACMD. Reducing opioid related deaths in the UK, December 2016. UK: Advisory Council on the Misuse of Drugs; 2016.
    1. Stenbacka M, Leifman A, Romelsjo A. Mortality and cause of death among 1705 illicit drug users: a 37 year follow up. Drug Alcohol Rev. 2010;29(1):21–27. doi: 10.1111/j.1465-3362.2009.00075.x.
    1. Baldacchino A, Armanyous M, Balfour DJ, Humphris G, Matthews K. Neuropsychological functioning and chronic methadone use: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;73:23–38. doi: 10.1016/j.neubiorev.2016.11.008.
    1. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89. doi: 10.1097/HRP.0000000000000052.
    1. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med. 2010;46(3):401–410.
    1. Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018;5(12):957–960. doi: 10.1016/S2215-0366(18)30303-1.
    1. Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795–806. doi: 10.1016/j.euroneuro.2018.03.017.
    1. Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396–1406. doi: 10.1111/add.14191.
    1. Phillips TJ, Reed C. Targeting GABAB receptors for anti-abuse drug discovery. Expert Opin Drug Discovery. 2014;9(11):1307–1317. doi: 10.1517/17460441.2014.956076.
    1. Bagley EE, Chieng BC, Christie MJ, Connor M. Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br J Pharmacol. 2005;146(1):68–76. doi: 10.1038/sj.bjp.0706315.
    1. Bagley EE, Hacker J, Chefer VI, Mallet C, McNally GP, Chieng BC, et al. Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors. Nat Neurosci. 2011;14(12):1548–1554. doi: 10.1038/nn.2940.
    1. Breslow MF, Fankhauser MP, Potter RL, Meredith KE, Misiaszek J, Hope DG., Jr Role of gamma-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry. 1989;146(3):353–356. doi: 10.1176/ajp.146.3.353.
    1. Drake RG, Davis LL, Cates ME, Jewell ME, Ambrose SM, Lowe JS. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother. 2003;37(9):1177–1181. doi: 10.1345/aph.1C465.
    1. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–1857. doi: 10.1111/j.1530-0277.2010.01273.x.
    1. Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology. 2021;46(13):2250–2256. doi: 10.1038/s41386-021-01055-w.
    1. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko A, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993;33(2):157–163. doi: 10.1016/0376-8716(93)90057-W.
    1. Sandyk R, Kwo-on-Yuen PF, Bamford CR. The effects of baclofen in the restless legs syndrome: evidence for endogenous opioid involvement. J Clin Psychopharmacol. 1988;8(6):440–441. doi: 10.1097/00004714-198812000-00017.
    1. Agabio R, Preti A, Gessa GL. Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur Addict Res. 2013;19(6):325–345. doi: 10.1159/000347055.
    1. Orr WC, Goodrich S, Wright S, Shepherd K, Mellow M. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil. 2012;24(6):553–9, e253. doi: 10.1111/j.1365-2982.2012.01900.x.
    1. Mackie SE, McHugh RK, McDermott K, Griffin ML, Winkelman JW, Weiss RD. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat. 2017;73:35–39. doi: 10.1016/j.jsat.2016.10.001.
    1. Raad S, Wilkerson M, Jones KR, Orr WC. The effect of baclofen on objective and subjective sleep measures in a model of transient insomnia. Sleep Med. 2020;72:130–134. doi: 10.1016/j.sleep.2020.03.028.
    1. Jaffe JH, Kanzler M, Brady R, Friedman L. Methodology for assessing agents that suppress methadone withdrawal: a study of baclofen. NIDA Res Monogr. 1982;41:269–275.
    1. Krystal JH, McDougle CJ, Kosten TR, Price LH, Aghajanian GK, Charney DS. Baclofen-assisted detoxification from opiates. A pilot study. J Subst Abuse Treat. 1992;9(2):139–142. doi: 10.1016/0740-5472(92)90081-X.
    1. Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. J Clin Pharm Ther. 2001;26(1):67–71. doi: 10.1046/j.1365-2710.2001.00325.x.
    1. Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther. 2000;25(5):347–353. doi: 10.1046/j.1365-2710.2000.00295.x.
    1. Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology. 2006;31(8):1814–1821. doi: 10.1038/sj.npp.1300999.
    1. Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581] BMC Psychiatry. 2003;3:16. doi: 10.1186/1471-244X-3-16.
    1. Gordon NC, Gear RW, Heller PH, Paul S, Miaskowski C, Levine JD. Enhancement of morphine analgesia by the GABAB agonist baclofen. Neuroscience. 1995;69(2):345–349. doi: 10.1016/0306-4522(95)00335-G.
    1. Li Y, Delcher C, Wei YJ, Reisfield GM, Brown JD, Tighe P, et al. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. Clin Pharmacol Ther. 2020;108(1):81–89. doi: 10.1002/cpt.1807.
    1. Panerai AE, Massei R, de Silva E, Sacerdote P, Monza G, Mantegazza P. Baclofen prolongs the analgesic effect of fentanyl in man. Br J Anaesth. 1985;57(10):954–955. doi: 10.1093/bja/57.10.954.
    1. Corli O, Roma G, Bacchini M, Battagliarin G, Di Piazza D, Brambilla C, et al. Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion. Clin Ther. 1984;6(6):800–807.
    1. Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018;27(11):1239–1248. doi: 10.1002/pds.4635.
    1. Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother. 1997;31(11):1315–1320. doi: 10.1177/106002809703101108.
    1. Mitsuboshi S. Association between baclofen and respiratory depression in patients with chronic kidney disease. J Clin Pharmacol. 2021;61(6):836–837. doi: 10.1002/jcph.1843.
    1. Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: drug experimentation in a group of adolescents. Pediatrics. 1998;101(6):1045–1048. doi: 10.1542/peds.101.6.1045.
    1. Correa D, Farney RJ, Chung F, Prasad A, Lam D, Wong J. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015;120(6):1273–1285. doi: 10.1213/ANE.0000000000000672.
    1. Olivier PY, Joyeux-Faure M, Gentina T, Launois SH, d’Ortho MP, Pepin JL, et al. Severe central sleep apnea associated with chronic baclofen therapy: a case series. Chest. 2016;149(5):e127–e131. doi: 10.1016/j.chest.2015.10.001.
    1. Finnimore AJ, Roebuck M, Sajkov D, McEvoy RD. The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J. 1995;8(2):230–234. doi: 10.1183/09031936.95.08020230.
    1. Durant CF, Paterson LM, Turton S, Wilson SJ, Myers JFM, Muthukumaraswamy S, et al. Using baclofen to explore GABA-B receptor function in alcohol dependence: insights from pharmacokinetic and pharmacodynamic measures. Front Psych. 2018;9:664. doi: 10.3389/fpsyt.2018.00664.
    1. Volpi R, Gerra G, Vourna S, Vescovi PP, Maestri D, Chiodera P, et al. Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in heroin addicts. Life Sci. 1992;51(4):247–251. doi: 10.1016/0024-3205(92)90082-Z.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Clark TP, Kahan BC, Phillips A, White I, Carpenter JR. Estimands: bringing clarity and focus to research questions in clinical trials. BMJ Open. 2022;12(1):e052953. doi: 10.1136/bmjopen-2021-052953.
    1. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group . Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health; 2017.
    1. NICE . Drug misuse in over 16s: opioid detoxification. NICE clinical guideline 52. London: National Institute for Health and Care Excellence; 2007.
    1. NICE . Methadone and buprenorphine for the management of opioid dependence. NICE technology appraisal guidance 114. London: National Institute for Health and Care Excellence; 2007.
    1. Schuckit MA, Gold EO. A simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls. Arch Gen Psychiatry. 1988;45(3):211–216. doi: 10.1001/archpsyc.1988.01800270019002.
    1. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O’Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) 2013;227(1):177–192. doi: 10.1007/s00213-012-2954-z.
    1. Jolley CJ, Bell J, Rafferty GF, Moxham J, Strang J. Understanding heroin overdose: a study of the acute respiratory depressant effects of injected pharmaceutical heroin. PLoS One. 2015;10(10):e0140995. doi: 10.1371/journal.pone.0140995.
    1. Tas B, Jolley CJ, Kalk NJ, van der Waal R, Bell J, Strang J. Heroin-induced respiratory depression and the influence of dose variation: within-subject between-session changes following dose reduction. Addiction. 2020;115(10):1954–1959. doi: 10.1111/add.15014.
    1. Royal College of Physicians . National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: Royal College of Physicians; 2017.
    1. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) 1980;71(2):173–179. doi: 10.1007/BF00434408.
    1. Nugent S, Katz MD, Little TE. Baclofen overdose with cardiac conduction abnormalities: case report and review of the literature. J Toxicol Clin Toxicol. 1986;24(4):321–328. doi: 10.3109/15563658608992596.
    1. Roberge RJ, Martin TG, Hodgman M, Benitez JG, Brunswick JE. Supraventricular tachyarrhythmia associated with baclofen overdose. J Toxicol Clin Toxicol. 1994;32(3):291–297. doi: 10.3109/15563659409017961.
    1. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res. 2009;33(1):19–30. doi: 10.1111/j.1530-0277.2008.00805.x.
    1. Gahr M, Freudenmann RW, Eller J, Schonfeldt-Lecuona C. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol. 2014;17(6):957–959. doi: 10.1017/S1461145713001600.
    1. Praharaj SK. Abuse liability of baclofen. Clin Psychopharmacol Neurosci. 2018;16(1):126–127. doi: 10.9758/cpn.2018.16.1.126.
    1. Farokhnia M, Schwandt ML, Lee MR, Bollinger JW, Farinelli LA, Amodio JP, et al. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017;7(4):e1108. doi: 10.1038/tp.2017.71.
    1. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504–508. doi: 10.1093/alcalc/37.5.504.
    1. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922. doi: 10.1016/S0140-6736(07)61814-5.
    1. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28(10):1517–1523. doi: 10.1097/01.ALC.0000141640.48924.14.
    1. Inserim Cnamts & ANSM . Le Baclofène en vie réelle en France entre 2009 et 2015. Usages, persistence et sécurité, et comparaison aux traitements des problems d’alcool ayant une authorisation demise sur le marché. 2017.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88(6):791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
    1. Humeniuk RE, Henry-Edwards S, Ali RL, Poznyak V, Monteiro M. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care. Geneva: World Health Organization; 2010.
    1. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90(5):607–614. doi: 10.1046/j.1360-0443.1995.9056072.x.
    1. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002;27(5):675–685. doi: 10.1016/S0306-4603(01)00201-5.
    1. Beck AT, Steer RA, Brown G. Beck Depression Inventory–II. APA psychTests. 1996.
    1. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1983.
    1. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540.
    1. Chung F, Abdullah HR, Liao P. STOP-Bang Questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631–638. doi: 10.1378/chest.15-0903.
    1. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS) J Psychoactive Drugs. 2003;35(2):253–259. doi: 10.1080/02791072.2003.10400007.
    1. RLS UK. Restless legs syndrome rating scale [Available from: ]. Accessed 11 Oct 2022.
    1. Sealed envelope. [Available from: ]. Accessed 11 Oct 2022.
    1. Mozgunov P, Cro S, Lingford-Hughes A, Paterson LM, Jaki T. A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial. Pharm Stat. 2022;21(2):476–495. doi: 10.1002/pst.2181.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Office for Health Improvement and Disparities. Adult substance misuse treatment statistics 2020 to 2021: report. UK: Office for Health Improvement and Disparities; 2021.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner